Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. - Wikidata - awgldk - TriplyDB

Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.

Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.

http://www.wikidata.org/entity/Q34984999

about

Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters Racial disparity in metabolic regulation of cancer.Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics.Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze.Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research.Direct infusion mass spectrometry for metabolomic phenotyping of diseases.Improved specificity of serum phosphatidylcholine detection based on side-chain losses during negative electrospray ionization tandem mass spectrometry.Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.Pancreatic cancer screening using a multiplatform human serum metabolomics system.Plasmalogen lipids: functional mechanism and their involvement in gastrointestinal cancer.

P2860

Q27022231-461483AB-9426-4703-B7CD-2BC030F02C4D Q33906704-85096068-B708-4409-A0E0-B083902132F2 Q35692287-78DEB281-7B8C-448B-8DF6-85D0AD488E23 Q36309665-1DAA35B0-8407-48E4-B8CC-8786C3D18E7F Q37720601-6CD7FF1D-1054-4F25-BA21-E899B731954B Q37733470-24127932-9838-4FF0-8C87-C63540E396F4 Q38366834-D8A97E73-A573-43BD-8F24-F15174E372AF Q38816181-010D91EE-D344-432B-87B4-B413D0C6C239 Q39029921-4DBDF974-FEEA-4F09-8D27-8D157C342DBB Q39030360-D757D986-F4AD-4D25-994C-DC2F553300A0 Q39452449-BAE11A42-6FD1-4ED4-AEFA-5BE725508960 Q42037878-67233B2D-5D16-4285-BD72-0A83ED9FBB16 Q42132357-D5B68FE4-C5C8-4D91-8EAB-563247C1451B Q42154484-3B6E5B93-711C-4ED8-9CC3-3269F1D6D946 Q46289482-D8CAA217-6BE1-4348-9A50-4625CF85A1E6 Q49701167-AFFAA4D3-6782-40B3-98F2-8D0168665649 Q52595056-5ADC2A10-6F67-4B1B-9828-4B13CE22D49F Q53102692-97B3F7BB-7D75-4412-BA66-3A050A47BAE2 Q54942543-59269BDF-9322-46F6-A0E0-0608DCF9B000

P2860

Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.

http://www.wikidata.org/entity/Q34984999

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Metabolic system alterations i ...... potential for early detection.

@ast

Metabolic system alterations i ...... potential for early detection.

@en

Metabolic system alterations i ...... potential for early detection.

@nl

type

label

Metabolic system alterations i ...... potential for early detection.

@ast

Metabolic system alterations i ...... potential for early detection.

@en

Metabolic system alterations i ...... potential for early detection.

@nl

prefLabel

Metabolic system alterations i ...... potential for early detection.

@ast

Metabolic system alterations i ...... potential for early detection.

@en

Metabolic system alterations i ...... potential for early detection.

@nl

P1433

Q34984999-965A4503-19AA-40E7-A5B0-44121DBFEB21

P1476

Q34984999-14074E94-0B21-4F41-8C1C-6611517B690A

P2093

Q34984999-00187778-1461-4697-90B8-604554898C13

Q34984999-051ADA40-741B-4D74-A816-DED20167C880

Q34984999-097E7D2B-4071-498C-B2FA-EF5C91EC534F

Q34984999-12AFF427-2592-4503-AFEB-221BD8C59DD4

Q34984999-2282A6C8-9287-4297-BBD8-60B5583E5936

Q34984999-40BE9B50-022A-432E-830C-D0F206097A74

Q34984999-6E2FBB65-0A89-466A-B2B7-61533A215DE0

Q34984999-6FA3A34D-B8E3-4F54-A478-10322A5DB9B2

Q34984999-81971472-A2BE-4B83-9B0A-6544CE85B198

Q34984999-848FEF9C-97EA-4E72-AA44-9043B92AAB66

P2860

Q34984999-002A8748-0C74-4C8E-BEA6-86C537DC7CD7

Q34984999-08A0B530-78E7-4FED-8021-B3F944D62805

Q34984999-0DB30C06-2E8A-4FEE-8423-2D21B6BE1D3F

Q34984999-1F625896-AC8C-4EF0-A4D6-390685A131FC

Q34984999-20E36BA1-447B-4B9B-BA55-808E4547F16F

Q34984999-251ED47E-EBAD-4E79-A294-303B2F215DB5

Q34984999-33F07431-1BC9-4FB5-BAF1-23229C50FC15

Q34984999-3C0A6014-FBBD-494C-B191-EABF60CCCDB8

Q34984999-3E5994B0-2BC7-4DC2-A75F-E28E741BD418

Q34984999-3EEBFD94-B483-426E-B7DA-A5C2AA488191

P2888

Q34984999-5CCF5BE4-99B4-49CF-AF17-2C05B4EA9572

P304

Q34984999-64C57803-81E3-43FF-BEB1-1ED3178BF70A

P31

Q34984999-8366F425-3D01-4026-80D8-B02A3AA0B003

P356

Q34984999-18BA424C-47D0-4618-82D9-DD8D7FFED0B3

P407

Q34984999-57D73CC0-5484-4E2D-900D-88ABC7D0F39D

P478

Q34984999-12A1F8A2-08FA-40D2-AC51-CA1ED6812E82

P50

Q34984999-EE4F9A9C-8613-49E5-8A56-D4CAA9A483BE

Q34984999-F632AA6C-092D-4206-9A64-3CBD746347E5

P577

Q34984999-7920BC11-9A5C-4F75-83E6-73D2DCEB95F6

P5875

Q34984999-0364DDDA-6C67-440A-8734-86E30D886B1B

P6179

Q34984999-68BA5E9B-DC49-4D72-9F31-6AC163A78FF1

P698

Q34984999-7EC1E99A-084E-4D17-9F41-B5885EFCF302

P921

Q34984999-6F94244C-69DA-48E8-A50C-20A9FA931DE1

P932

Q34984999-BADAB9E2-BBDF-459D-80C0-16774C59D51F

P356

1471-2407-13-416

P1433

P1476

Metabolic system alterations i ...... potential for early detection.

@en

P2093

Bassirou Chitou

http://www.w3.org/2001/XMLSchema#string

Dayan B Goodenowe

http://www.w3.org/2001/XMLSchema#string

Dushmanthi Jayasinghe

http://www.w3.org/2001/XMLSchema#string

Elodie Pastural

http://www.w3.org/2001/XMLSchema#string

Hidetoshi Eguchi

http://www.w3.org/2001/XMLSchema#string

Hiroaki Nagano

http://www.w3.org/2001/XMLSchema#string

Hirofumi Akita

http://www.w3.org/2001/XMLSchema#string

Ichiro Takemasa

http://www.w3.org/2001/XMLSchema#string

Morito Monden

http://www.w3.org/2001/XMLSchema#string

Shawn A Ritchie

http://www.w3.org/2001/XMLSchema#string

P2860

Lifestyle-related factors and environmental agents causing cancer: An overview

Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

Early detection of pancreatic cancer: why, who, and how to screen

Plasmalogens: biosynthesis and functions

Exclusive localization in peroxisomes of dihydroxyacetone phosphate acyltransferase and alkyl-dihydroxyacetone phosphate synthase in rat liver

Cancer statistics, 2009

Controlling the false discovery rate in behavior genetics research

Mass spectrometry-based metabolomics.

P2888

1471-2407-13-416

P304

416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-416

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256499939

http://www.w3.org/2001/XMLSchema#string

P6179

1032610708

http://www.w3.org/2001/XMLSchema#string

P698

24024929

http://www.w3.org/2001/XMLSchema#string

P921

P932

3847543

http://www.w3.org/2001/XMLSchema#string